Top

Breast Cancer Research and Treatment

Published in:

01-05-2020 | Breast Cancer | Epidemiology

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience

Authors: J. Watanabe, M. Saito, Y. Horimoto, S. Nakamoto

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Abstract

Purpose

Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2−ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. Recently, a maintained baseline lymphocyte count was proposed as predictive marker for eribulin therapy in HER2−ABC patients; however, no associations with the OS have been noted. We retrospectively investigated the neutrophil-to-lymphocyte ratio and absolute lymphocyte count (ALC) in HER2−ABC patients receiving eribulin and assessed the utility of eribulin re-administration for further OS improvement.

Methods

HER2−ABC patients who received eribulin therapy at Shizuoka Cancer Center between November 2011 and December 2018 were retrospectively analyzed.

Results

A total of 144 HER2−ABC (108 estrogen receptor-positive [ER+], 36 ER−) patients were identified, and 32 patients (28 ER+ , 4 ER−) were re-administered with eribulin. In the ER+ subgroup, a multivariate analysis showed that an ALC ≥ 1000/μL and re-administration were significantly associated with the OS (hazard ratio [HR] 0.503; P = 0.034 and HR 0.366; P < 0.0001, respectively), and an ALC ≥ 1000/μL was also identified as the only predictive factor for re-administration (HR 0.329; P = 0.033). In contrast, a multivariate analysis in the ER- subgroup identified no predictive markers.

Conclusion

In HER2−ER + ABC patients, ALC was identified as a predictive marker for eribulin therapy, and the re-administration of eribulin is considered a valid therapeutic option for further improvement of the OS.

Available only for authorised users

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet 377:914–923. https://doi.org/10.1016/s0140-6736(11)60070-6 CrossRef

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33:594–601. https://doi.org/10.1200/JCO.2013.52.4892 CrossRefPubMedPubMedCentral

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28:16–33. https://doi.org/10.1093/annonc/mdw544 CrossRefPubMed

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922–3928. https://doi.org/10.1200/JCO.2009.25.8467 CrossRefPubMed

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110:1497–1505. https://doi.org/10.1038/bjc.2014.80 CrossRefPubMedPubMedCentral

Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334–1342. https://doi.org/10.1111/cas.12488 CrossRefPubMedPubMedCentral

Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, Osaki A (2016) In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 114:1212–1218. https://doi.org/10.1038/bjc.2016.122 CrossRefPubMedPubMedCentral

Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M (2018) Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res 38:2929–2938. https://doi.org/10.21873/anticanres.12541 CrossRefPubMed

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148:553–561. https://doi.org/10.1007/s10549-014-3144-y CrossRefPubMedPubMedCentral

10.

Kashiwagi S, Tsujio G, Asano Y, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2018) Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. J Transl Med. https://doi.org/10.1186/s12967-018-1443-5 CrossRefPubMedPubMedCentral

11.

Iwai Y, Terawaki S, Honjo T (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17:133–144. https://doi.org/10.1093/intimm/dxh194 CrossRefPubMed

12.

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16:4583–4594. https://doi.org/10.1158/1078-0432.Ccr-10-0733 CrossRefPubMed

13.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205 CrossRefPubMed

14.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentral

15.

Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224. https://doi.org/10.1245/s10434-011-1814-0 CrossRefPubMed

16.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https://doi.org/10.1093/jnci/dju124 CrossRefPubMed

17.

Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, Taib NA (2015) Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113:150–158. https://doi.org/10.1038/bjc.2015.183 CrossRefPubMedPubMedCentral

18.

Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, Ridolfi F, Santoni M, Maccaroni E, Bracci R, Santinelli A, Biscotti T, Berardi R, Cascinu S (2015) Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer 15:195. https://doi.org/10.1186/s12885-015-1204-2 CrossRefPubMedPubMedCentral

19.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K (2016) Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol 23:1104–1110. https://doi.org/10.1245/s10434-015-4934-0 CrossRefPubMed

20.

Papatestas AE, Lesnick GJ, Genkins G, Aufses AH Jr (1976) The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma. Cancer 37:164–168. https://doi.org/10.1002/1097-0142(197601)37:1%3c164:aid-cncr2820370123%3e3.0.co;2-h CrossRefPubMed

21.

Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, Nishimukai A, Kira A, Imamura M, Takatsuka Y, Miyoshi Y (2018) Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer 18:400–409. https://doi.org/10.1016/j.clbc.2018.03.002 CrossRefPubMed

22.

De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M (2012) Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 12:264–269. https://doi.org/10.1016/j.clbc.2012.04.004 CrossRefPubMed

23.

Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Menetrier-Caux C (2013) Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer 49:1673–1682. https://doi.org/10.1016/j.ejca.2012.11.028 CrossRefPubMed

24.

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383–5391. https://doi.org/10.1158/0008-5472.Can-08-3845 CrossRefPubMedPubMedCentral

25.

Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Ohno S, Miyoshi Y (2018) Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer 18:982. https://doi.org/10.1186/s12885-018-4888-2 CrossRefPubMedPubMedCentral

26.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW (2018) Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 24:2851–2858. https://doi.org/10.1158/1078-0432.Ccr-17-1323 CrossRefPubMedPubMedCentral

27.

Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27:1533–1541CrossRefPubMed

28.

Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R (2007) Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133–5143. https://doi.org/10.1158/1078-0432.Ccr-07-0507 CrossRefPubMed

29.

Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, Asano M, Asano O, Yokoi A, Matsui J, Umeda IO, Fujii H (2017) Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci 108:2273–2280. https://doi.org/10.1111/cas.13392 CrossRefPubMedPubMedCentral

30.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2017) Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS ONE 12:e0170634. https://doi.org/10.1371/journal.pone.0170634 CrossRefPubMedPubMedCentral

31.

Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N (2013) Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. Chemotherapy 59:307–313. https://doi.org/10.1159/000356155 CrossRefPubMed

32.

Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K (2019) Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer 132:54–58. https://doi.org/10.1016/j.lungcan.2019.02.021 CrossRefPubMed

33.

Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA (2015) "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res 17:150. https://doi.org/10.1186/s13058-015-0657-1 CrossRefPubMedPubMedCentral

34.

Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, Puglisi F (2015) Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? Oncologist 20:719–724. https://doi.org/10.1634/theoncologist.2015-0002 CrossRefPubMedPubMedCentral

35.

Watanabe J (2015) Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus 4:625. https://doi.org/10.1186/s40064-015-1422-8 CrossRefPubMedPubMedCentral

Title: A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
Authors: J. Watanabe
M. Saito
Y. Horimoto
S. Nakamoto
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05626-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes

The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients

Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers

Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome

Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival

Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner

Keynote webinar | Spotlight on antibody–drug conjugates in cancer